Efficacy and safety of bortezomib + thalidomide + dexamethasone (VTd) as consolidation therapy in patients with newly diagnosed multiple myeloma that reached PR at completion of VTd induction

Trial Profile

Efficacy and safety of bortezomib + thalidomide + dexamethasone (VTd) as consolidation therapy in patients with newly diagnosed multiple myeloma that reached PR at completion of VTd induction

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2014

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2014 New trial record
    • 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top